Pharmaceutical company Élan has announced that an advisory committee in the US has recommended approval of its Tysabri drug as a treatment for Crohn's disease.
The ruling by the Gastrointestinal Drugs Advisory Committee is not binding on the US Food & Drug Administration, which has the final say.
Élan and its partner Biogen said they would work closely with the FDA in the weeks ahead to secure full approval.
The advisory group backed Tysabri's use as a treatment for moderate to severe Crohn's in patients who have failed or cannot tolerate available therapies.
